Deflazacort
It is a glucocorticoid. Its anti-inflammatory and immunosuppressive effects are used in treating a variety of disease and are comparable to other anti-inflammtory steroids.Rheumatoid Arthritis & Juvenile Chronic Arthritis, Asthma and other airway diseases, Pemphigus, Uveitis, Nephrotic Syndrome, Immunne suppression in transplantation.
The dosage should be individually titrated according to diagnosis, severity of disease and patient response and tolerance. The lowest dose that will produce an acceptable response should be used. Adults : For acute disorders, up to 120mg/day deflazacort may need to be given initially. Maintainance dosese in most conditions are within the range 3-18mg/day. Children : In children, the indications for glucocorticoids are the same as for adults, but it is important that the lowest effective dosag
Hypersensitivity. Patients receiving live virus immunisation.
Adrenal suppression, Cardiac diseases or congestive heart failure (except in the presence of active rheumatic carditis), hypertension, thromboembolic disorders. Gastritis or oesophagitis, diverticulitis, ulcerative colitis if there is probalility of impending perforation, abscess or pyogenic infections, fresh intestinal anastomsis, active or latent peptic ulcer. Diabetic mellitus or a family history, osteoporosis, myasthenia gravis, renal insufficiency. Emotional instability or psychotic tendency, epilepsy. Previous corticosteroid-induced myopathy, Liver failure, Hypothyroidism and cirrhosis, Ocular herpes simplex, Pregnant woman, Lactation,
Gastrointestinal symptoms are the most frequently reported adverse events.
-Strong CYP3A4 inhibitors and inducers, affecting drug plasma levels. -Nonsteroidal anti-inflammatory drugs (NSAIDs), which may increase the risk of gastrointestinal ulcers. - Immunosuppressants, such as cyclosporine, which may potentiate their effects.